Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4446 - A phase II randomised study of Adjuvant hypo-fractionated radiotherapy with Concurrent vs Sequential Letrozole in post-menopausal women with Hormone receptor positive Breast Cancer: Report of Pulmonary toxicity and cosmetic outcome


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Surgical Oncology;  Radiation Oncology;  Breast Cancer


Rituraj Upadhyay


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


R. Upadhyay1, D.N. Sharma1, P. Julka2, G.K. Rath3

Author affiliations

  • 1 Radiation Oncology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 2 Medical Oncology, B.R. Ambedkar Institute Rotary Cancer Hospital (AIMS), 110029 - New Delhi/IN
  • 3 Radiation Oncology, B.R. Ambedkar Institute Rotary Cancer Hospital (AIMS), 110029 - New Delhi/IN


Abstract 4446


The sequence of hormonal therapy with adjuvant radiation(RT) is debated because of anticipated morbidity. We conducted a phase II study to evaluate feasibility and efficacy of concurrent and sequential letrozole along-with hypo-fractionated RT(HFRT).


A total of 50 Post-menopausal women with hormone-receptor positive, Stage I-III Breast cancer received adjuvant HFRT 42.5Gy/16fr/3weeks and were randomly assigned to either concurrent (arm A) or sequential letrozole (arm B). Letrozole was started 3 weeks before RT in the concurrent, and 3 weeks after RT in sequential group. Pulmonary toxicity was assessed by clinical examination, chest x-ray, pulmonary function tests and HRCT chest (if indicated) at baseline, at one and six months(m) post RT. Cosmetic outcome was reported in both arms with six parameters (Table) at 6 m post RT.


A total of 48 patients(pts) were followed up for 6 m (25 in Arm A and 23 in Arm B). None of the pts developed acute pulmonary toxicities. Mean (R) FeV1 and FVC values at baseline, 1 and 6 m post RT were 1.8 l (1.6-1.9) and 2.2 l(2.1-2.4), 1.79 l(1.5-1.9) and 2.1 l(1.9-2.4) and 1.85 l(1.6-2) and 2.2 l(2-2.4) respectively, and were comparable. FeV1 and FVC remained within 80 to 120% of the baseline values in 37 pts (20 Arm A vs 17 Arm B, p = 0.5). FeV1 and FVC were reduced by more than 80% at 6 m in 3 pts of Arm A and 5 pts in Arm B, (p = 0.7), while this was improved by over 120% in 5 pts (2 vs 3, p = 1). RTOG grade 2-3 radiation dermatitis was seen in 33 pts (15 vs 18, p = 0.55) while 5 pts had grade 4 toxicity (2 vs 3, p = 1). There was no treatment interruption because of toxicity.Table:


Cosmetic Outcome
Mild changeMarked change
Breast Shrinkage6523
Breast Hardness22 10
Breast Swelling100 0
Change in Skin appearance9833
Self-breast assessment141355
Photographic breast assessment151532

Overall, 18 pts had excellent cosmesis (7 vs 11, p = 0.4) while 32 had good cosmesis. (18 vs 14, p = 0.4).


HFRT along-with concurrent Letrozole is well tolerated. However, patients are being followed to assess loco-regional disease control and late toxicities.

Clinical trial identification

Legal entity responsible for the study

All India Institute of Medical Sciences




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.